These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 6137869)

  • 1. The interaction between GABA and dopamine: implications for schizophrenia.
    Garbutt JC; van Kammen DP
    Schizophr Bull; 1983; 9(3):336-53. PubMed ID: 6137869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. gamma-Aminobutyric acid (Gaba) and the dopamine hypothesis of schizophrenia.
    Van Kammen DP
    Am J Psychiatry; 1977 Feb; 134(2):138-43. PubMed ID: 835733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Dopaminergic receptor activity and the evolution of schizophrenia].
    Fodoreanu L
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Neurol Psihiatr Neurochir; 1985; 30(2):131-4. PubMed ID: 2864729
    [No Abstract]   [Full Text] [Related]  

  • 4. BL-1020: a novel antipsychotic drug with GABAergic activity and low catalepsy, is efficacious in a rat model of schizophrenia.
    Geffen Y; Nudelman A; Gil-Ad I; Rephaeli A; Huang M; Savitsky K; Klapper L; Winkler I; Meltzer HY; Weizman A
    Eur Neuropsychopharmacol; 2009 Jan; 19(1):1-13. PubMed ID: 18757185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Critical review of GABA-ergic drugs in the treatment of schizophrenia.
    Wassef AA; Dott SG; Harris A; Brown A; O'Boyle M; Meyer WJ; Rose RM
    J Clin Psychopharmacol; 1999 Jun; 19(3):222-32. PubMed ID: 10350028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence.
    Carlsson A; Waters N; Holm-Waters S; Tedroff J; Nilsson M; Carlsson ML
    Annu Rev Pharmacol Toxicol; 2001; 41():237-60. PubMed ID: 11264457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interactions of 5-hydroxytryptamine and gamma-aminobutyric acid with dopamine.
    Pycock CJ; Horton RW; Carter CJ
    Adv Biochem Psychopharmacol; 1978; 19():323-41. PubMed ID: 358783
    [No Abstract]   [Full Text] [Related]  

  • 8. Clozapine, GABA(B), and the treatment of resistant schizophrenia.
    Daskalakis ZJ; George TP
    Clin Pharmacol Ther; 2009 Oct; 86(4):442-6. PubMed ID: 19626000
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects of putative dopamine autoreceptor agonists in pharmacological models related to dopaminergic and neuroleptic activity.
    Arnt J; Christensen AV; Hyttel J; Larsen JJ; Svendsen O
    Eur J Pharmacol; 1982 Dec; 86(2):185-98. PubMed ID: 6130958
    [No Abstract]   [Full Text] [Related]  

  • 10. The role of dopamine and GABA in the frontal cortex of mice in modulating a motor-stimulant effect of amphetamine and cocaine.
    Karler R; Calder LD; Thai DK; Bedingfield JB
    Pharmacol Biochem Behav; 1998 May; 60(1):237-44. PubMed ID: 9610948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurotransmitters and CNS disease. Schizophrenia.
    Snyder SH
    Lancet; 1982 Oct; 2(8305):970-4. PubMed ID: 6127468
    [No Abstract]   [Full Text] [Related]  

  • 12. Neural circuitry models of schizophrenia: is it dopamine, GABA, glutamate, or something else?
    Benes FM
    Biol Psychiatry; 2009 Jun; 65(12):1003-5. PubMed ID: 19481640
    [No Abstract]   [Full Text] [Related]  

  • 13. Dopamine, the prefrontal cortex and schizophrenia.
    Knable MB; Weinberger DR
    J Psychopharmacol; 1997; 11(2):123-31. PubMed ID: 9208376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brain imaging of schizophrenia--the dopamine hypothesis.
    Farde L
    Schizophr Res; 1997 Dec; 28(2-3):157-62. PubMed ID: 9468350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GABA-dopamine interaction in substantia nigra and nucleus accumbens--relevance to behavioral stimulation and stereotyped behavior.
    Scheel-Krüger J; Arnt J; Braestrup C; Christensen AV; Cools AR; Magelund G
    Adv Biochem Psychopharmacol; 1978; 19():343-6. PubMed ID: 567933
    [No Abstract]   [Full Text] [Related]  

  • 16. The dopamine hypothesis of schizophrenia revisited.
    van Kammen DP
    Psychoneuroendocrinology; 1979 Jan; 4(1):37-46. PubMed ID: 39306
    [No Abstract]   [Full Text] [Related]  

  • 17. GABA and schizophrenia: a review of basic science and clinical studies.
    Wassef A; Baker J; Kochan LD
    J Clin Psychopharmacol; 2003 Dec; 23(6):601-40. PubMed ID: 14624191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Social and neural determinants of aggressive behavior: pharmacotherapeutic targets at serotonin, dopamine and gamma-aminobutyric acid systems.
    Miczek KA; Fish EW; De Bold JF; De Almeida RM
    Psychopharmacology (Berl); 2002 Oct; 163(3-4):434-58. PubMed ID: 12373445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Biochemistry of schizophrenia and mechanism of action of neuroleptics].
    Loo H; Cuche H; Sechter D
    Sem Hop; 1982 Dec; 58(44):2565-72. PubMed ID: 6130604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A schizophrenia-related sensorimotor deficit links alpha 3-containing GABAA receptors to a dopamine hyperfunction.
    Yee BK; Keist R; von Boehmer L; Studer R; Benke D; Hagenbuch N; Dong Y; Malenka RC; Fritschy JM; Bluethmann H; Feldon J; Möhler H; Rudolph U
    Proc Natl Acad Sci U S A; 2005 Nov; 102(47):17154-9. PubMed ID: 16284244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.